The overarching goal of our study is the design of a potential novel therapeutic strategy for advanced HER2+ GC, for instance, by cotargeting HER2 and FASN oncogenic/metabolic axis to eradicate both the root of cancer and the bulk of the tumor mass. Here, ERBB2 is linked to neoplasm.